Official websites use .gov

A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS

A lock ( 🔒 ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

Need Help

Micro-Organospheres Drug Screen to Lead Care (MODEL): a Precision Oncology Platform to Guide Breast Cancer Therapy

Award Number: R44CA261579
ORGANIZATION: NATIONAL CANCER INSTITUTE
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 05/09/2022
PERIOD OF PERFORMANCE END DATE: 05/13/2024

Group Awards By:

View Award Description

Micro-Organospheres Drug Screen to Lead Care (MODEL): a Precision Oncology Platform to Guide Breast Cancer Therapy - PROJECT SUMMARY/ABSTRACT The goal of precision oncology is to match cancer patients with medicines based on the specific biology of their tumor. Crucially, the current precision oncology paradigm – which is largely based on tumor genomic profiling – doesn’t work for the majority of patients. Since every patient’s tumor is uniquely complex, a potential solution to this “precision” problem involves creating a viable functional model of a patient’s individual tumor in order to directly test its susceptibility to different drugs. The broad adoption of such patient-derived functional models into the clinic thus far has been hindered by several limitations centered on scalability, time, and success rate. Specifically, any assay for guiding therapy must be: i) amenable to the amount of material derived from needle biopsies, ii) established with a high success rate, and iii) completed within 10-14 days to minimize unacceptable treatment delays. To address these clinical limitations, we have developed the novel Micro-Organosphere Drug Screen to Lead Care (MODEL) platform. MODEL is based on novel microfluidics technology that generates Patient-Derived Micro-Organospheres (PDMO) from clinical samples (e.g., biopsies) and performs drug screening within 10 days to guide therapy. The objective of our proposal is to further develop and validate our MODEL technology in breast cancer, with a view to advancing it further towards becoming a standard of care diagnostic assay. Phase I of our proposal will focus on preparing our MODEL device for rigorous clinical evaluation. In Aim 1 we will make key upgrades to our device prototype to improve sample efficiency, device performance, and operability. Specifically, the goal of these improvements will be to reduce sample size requirements (extending our capabilities down to fine-needle aspirates), enhance device performance, reinforce consistency of key parameters during and between runs, and increase process automation. In Aim 2, we will rigorously test the ability of our second-generation device to i) successfully generate PDMO from breast cancer biopsies and ii) perform drug screens in less than 10 days total. In Phase II, we will make key device upgrades to prepare the MODEL platform for commercialization, focusing on improving features related to data integrity and ease-of-use (Aim 1). In Aim 2 we will perform the first validation of our MODEL platform in a HER2+ breast cancer clinical protocol consisting of 50 patients, with the goal of testing MODEL’s ability to predict response to standard of care neoadjuvant therapy. If successful, the development of our platform will revolutionize precision oncology by arming oncologists with the information needed to optimally match cancer patients with medicines.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2025 ( Subtotal = -$998,506 )
2025	2023	XILIS INC	31 ALEXANDRIA WAY	DURHAM	NC	27703	DURHAM	USA	Cancer Biology Research	000	2	10/10/2024	EXTENSION WITH OR WITHOUT FUNDS	-$998,506
														Subtotal = -$998,506

Issue Date FY: 2024 ( Subtotal = $0 )
2024	2023	XILIS INC	31 ALEXANDRIA WAY	DURHAM	NC	27703	DURHAM	USA	Cancer Biology Research	001	2	8/2/2024	EXTENSION WITH OR WITHOUT FUNDS	$0
2024	2022	XILIS INC	31 ALEXANDRIA WAY	DURHAM	NC	27703	DURHAM	USA	Cancer Biology Research	000	1	5/2/2024	NEW	$0
														Subtotal = $0

Issue Date FY: 2023 ( Subtotal = $998,506 )
2023	2023	XILIS INC	31 ALEXANDRIA WAY	DURHAM	NC	27703	DURHAM	USA	Cancer Biology Research	000	2	9/1/2023	EXTENSION WITH OR WITHOUT FUNDS	$998,506
														Subtotal = $998,506

Issue Date FY: 2022 ( Subtotal = $398,486 )
2022	2022	XILIS, INC.	113 EASTWOOD LAKE RD	CHAPEL HILL	NC	27514	ORANGE	USA	Cancer Biology Research	000	1	5/6/2022	NEW	$398,486
														Subtotal = $398,486

Grand Total All Awards = $398,486

Top

All Categories

About

Search

Reports

Data Submission

Award Information

Micro-Organospheres Drug Screen to Lead Care (MODEL): a Precision Oncology Platform to Guide Breast Cancer Therapy

Award Number: R44CA261579

ORGANIZATION: NATIONAL CANCER INSTITUTE

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 05/09/2022

PERIOD OF PERFORMANCE END DATE: 05/13/2024

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer